Veraxa Biotech Completes Nasdaq Listing, Secures $77.5M for Cancer Therapy Pipeline
VRXA has more than doubled off its 52-week low of $8.4 on elevated volume (2.0× avg).
Summary
Veraxa Biotech AG has successfully completed its business combination with Voyager Acquisition Corp., leading to its Nasdaq listing under the ticker VRXA and securing up to $77.5 million in new financing to advance its oncology pipeline.
Key Events · Financing and Capital Events · VRXA
-
Nasdaq Listing Completed
Veraxa Biotech AG (formerly Veraxa Biotech Holding AG) completed its business combination with Voyager Acquisition Corp. and commenced trading its shares (VRXA) and warrants (VRXAW) on the Nasdaq Capital Market on June 11, 2026.
-
Significant Financing Secured
The company secured a $27.5 million senior secured note and a share purchase agreement for up to $50 million, totaling up to $77.5 million in new capital.
-
Pipeline Advancement Funded
The proceeds from the financings will fund the advancement of Veraxa's BiTAC-TCE and BiTAC-ADC oncology programs towards clinical development.
-
Positive Pre-clinical Data Presented
Recent data presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting showed promising results for its BiTAC platform, demonstrating superior safety and matching efficacy compared to traditional T-cell engagers.
Analysis · VRXA · Life Sciences
This event marks a significant transformation for Veraxa Biotech, transitioning to a publicly traded company on Nasdaq. The successful completion of the business combination provides the company with enhanced visibility and access to capital markets. The secured financing of up to $77.5 million is substantial, representing nearly 10% of its current market capitalization, and is crucial for funding the clinical development of its next-generation cancer therapies. The positive pre-clinical data for its BiTAC platform further validates its technology and strengthens the investment thesis as the company moves towards key value inflection points in its pipeline.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRXA was trading at $24.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $784M. The 52-week trading range was $8.40 to $27.36. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.